New Therapy Targeting Mitochondrial Health Enters Clinical Trial

Pretzel Therapeutics has launched a Phase 1 clinical trial to evaluate PX578, a potential therapy aimed at improving the health of mitochondria—the parts of cells responsible for producing energy. Mitochondrial dysfunction is known to play a role in various rare genetic diseases and neurodegenerative conditions, including Parkinson’s and Alzheimer’s. Study Focus and Design The trial will take place in New Zealand and will enroll up to 112 healthy volunteers. Its goal is to assess the safety, tolerability, and processing of PX578 in the body by administering increasing doses of the therapy, both as single and repeated doses. The study is expected to begin by the end of the month. How PX578 Works PX578 is a small molecule designed to activate POLG, an enzyme that helps repair and copy mitochondrial DNA (mtDNA). Since mtDNA is essential for the mitochondria’s ability to generate energy, enhancing its function may lead to improved cellular energy production—something that could be especially beneficial in conditions like Parkinson’s, where mitochondrial damage contributes to disease progression. Potential Impact on Parkinson’s Disease While this early trial focuses on healthy individuals, future studies are planned for people living with mitochondrial DNA depletion syndromes, with a trial expected in 2026. PX578 is also being investigated for its relevance to Parkinson’s, supported by a grant from Parkinson’s UK. This research, in collaboration with the Karolinska Institute, aims to better understand how PX578 might help preserve brain health by protecting mitochondrial function. A Hopeful Step Forward Though PX578 is still in early stages of development, it represents a promising approach to addressing energy loss in cells—a common factor in many neurological conditions. Researchers hope that by targeting the root of mitochondrial dysfunction, this therapy could one day offer new options for slowing the progression of diseases like Parkinson’s, where current treatments mainly focus on managing symptoms.